Overactive Bladder Treatment (OAB) Market Share, Size, Trends, Industry Analysis Report, By Therapy; By Disease Type (Idiopathic Overactive Bladder, Neurogenic Overactive Bladder); By Region; Segment Forecast, 2022-2030

Overactive Bladder Treatment (OAB) Market Share, Size, Trends, Industry Analysis Report, By Therapy; By Disease Type (Idiopathic Overactive Bladder, Neurogenic Overactive Bladder); By Region; Segment Forecast, 2022-2030

The global overactive bladder treatment market size is expected to reach USD 5.2 billion by 2030, according to a new study by Polaris market research. The report “Overactive Bladder Treatment (OAB) Market Share, Size, Trends, Industry Analysis Report, By Therapy; By Disease Type (Idiopathic Overactive Bladder, Neurogenic Overactive Bladder); By Region; Segment Forecast, 2022-2030” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The growing geriatric population and the prevalence of urinary incontinence are the key factors propelling the global market. The next-generation implant, sacral neuromodulation for OAB, is less risky, longer-lasting, and more user-friendly. For instance, in February 2022, the US health authorities approved Alembic Pharmaceutical’s extended-release tablet, “Fesoterodine Fumarate,” which treats individuals with overactive bladder symptoms. Fesoterodine fumarate extended-release tablets in strengths of 4 & 8 mg have also submitted ANDA application.

Furthermore, pharmaceutical and biopharmaceutical companies are now investing in cutting-edge medicines for the treatment of overactive bladders, which are anticipated to be introduced throughout the projected period. For instance, Taiho Pharmaceutical is working on the Phase II-ready medication TAC-302. This medication is orally accessible and works by promoting neurite outgrowth activity in cultured peripheral neurons to treat overactive bladder. When new treatment alternatives are introduced, more people will use them, increasing treatment uptake and so fueling market expansion.

A considerable portion of the population suffers from overactive bladder, a persistent medical problem. In the upcoming years, the market expansion might be constrained by frequent recalls of OAB-treating medications. AbbVie announced in February 2022 that the US FDA approved BOTOX treatment for the detrusor (bladder muscle) over-activity aligned with the neurologic condition in pediatric patients aged five or older who have a sub-optimal response to or the in-tolerable of anti-cholinergic medication. Regular recalls hampering market expansion for overactive bladder treatments by top pharmaceutical companies.

COVID-19 is anticipated to have a significant influence on the market for overactive bladder treatment. This is primarily brought on by the COVID-19 recovered patients’ worsening overactive bladder symptoms. Several studies have referred to it as COVID-19-related cystitis (CAC). The market is therefore anticipated to show expansion during the anticipated period as a result of the aforementioned factors. However, the adverse consequences of the existing therapy can prevent the market from expanding.

Overactive Bladder Treatment Market Report Highlights

The market is anticipated to be dominated by Mirabegron in 2021. When compared to other pharmacological classes on the market, this industry’s lower side-effect profile is one of its main growth drivers

The idiopathic overactive bladder segment retained a bigger market share in 2021, owing to the higher prevalence of idiopathic overactive bladder illnesses and the increasing use of pharmaceuticals for treatment.

The majority of the market was controlled by North America. The market is anticipated to expand throughout the course of the projection period because overactive bladder treatment is covered by insurance, the disease is anticipated to become more common as people age, and presence of large firms in the region.

The global players include AbbVie, Astellas Pharma, Laborie, Endo International PLC, Hisamitsu Pharmaceutical, Johnson & Johnson Services, Medtronic, Pfizer, Sanofi, and Viatris.

Polaris Market Research has segmented the Overactive Bladder Treatment Market report based on therapy, disease type, and region:

Overactive Bladder Treatment, Therapy Outlook (Revenue – USD Billion, 2018 – 2030)

Anticholinergics

Mirabegron

Neurostimulation

Intravesical Instillation

Other Therapies

Overactive Bladder Treatment, Disease Type Outlook (Revenue – USD Billion, 2018 – 2030)

Idiopathic Overactive Bladder

Neurogenic Overactive Bladder

Overactive Bladder Treatment, Regional Outlook (Revenue – USD Billion, 2018 – 2030)

North America

U.S

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa